Nature Reviews Clinical Oncology - Table of Contents alert Volume 10 Issue 9

Advertisement
New model systems to advance understanding of serous epithelial ovarian cancer  Topic editors: Elise Kohn and Viive M. Howell¦ Submission deadline: 30/09/13 This Frontiers in Oncology Research Topic will showcase new model systems for SEOC research including normal, cancerous and cancer-associated cell lines and their use in 2D, 3D and co-culture systems as well as in vivo approaches that utilize the latest advances in transgenics and imaging.  Find out more on how you can contribute to this RT.
TABLE OF CONTENTS
September 2013 Volume 10 Number 9
Impact Factor 15.031 *	In this issue Research Highlights News and Views Reviews Correspondence Also this month  Featured article: Luminal breast cancer: from biology to treatment Michail Ignatiadis & Christos Sotiriou
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Reprint Collection MicroRNAs from bench to clinic This Nature Reprint Collection presents some of the recent advances in moving microRNAs from basic research into the clinic both as diagnostic biomarkers and therapeutic targets.  Click here to access the Collection for free!   Produced with support from:
RESEARCH HIGHLIGHTS Top Genetics: A molecular atlas of clear cell renal cell carcinoma Published online: 09 July 2013 p485 | doi:10.1038/nrclinonc.2013.122 PDF Epidemiology: Time to ESCAPE the city? Air pollution linked to lung cancer Published online: 23 July 2013 p486 | doi:10.1038/nrclinonc.2013.136 PDF Urological cancer: Nerves linked to prostate cancer Published online: 30 July 2013 p487 | doi:10.1038/nrclinonc.2013.139 PDF Imaging: Novel glucose uptake imaging method Published online: 16 July 2013 p488 | doi:10.1038/nrclinonc.2013.130 PDF Targeted therapies: The maths behind combination therapy Published online: 16 July 2013 p488 | doi:10.1038/nrclinonc.2013.131 PDF Genetics: APOBEC—a double-edged sword Published online: 30 July 2013 p488 | doi:10.1038/nrclinonc.2013.138 PDF IN BRIEF Gynaecological cancer: Evaluating ovarian cancer cell lines as tumour models | Breast cancer: Comparison of risk-of-recurrence scores in breast cancer | Urological cancer: Serum androgens levels are prognostic in prostate cancer | Health policy: Lack of research on link between cancer and mental health | Bone cancer: Denosumab—new treatment option for GCTB | Haematological cancer: ATRA and arsenic trioxide treatment for leukaemia | Gynaecological cancer: Declining use of brachytherapy for cervical cancer in USA | Epidemiology: Benefit for low-dose, alternate-day aspirin use for CRC PDF Clinical Oncology JOBS of the week Radiochemist Hadassah Hebrew University Hospital, Cyclotron- Radiochemistry- microPET unit Director of Upper Aerodigestive Cancer Program Johns Hopkins University Post Doctoral Associate Yale Cancer Center | Yale School of Medicine Postdoctoral Fellowship University of Science & Technology of China Research Associate Professor (non-tenured) University of Science & Technology of China More Science jobs from Clinical Oncology EVENT 3rd Annual Oncology Biomarkers Congress 14.10.13 Manchester, UK More science events from
NEWS AND VIEWS		Top
Skin cancer: Basal cell carcinoma—pay your money, take your choice Ervin H. Epstein Jr Published online: 23 July 2013 p489 | doi:10.1038/nrclinonc.2013.133 Superficial basal cell carcinomas are a common challenge in clinical dermatology because they are frequent and surgical approaches tend to scar. A large randomized trial comparing three nonsurgical approaches has shown that all had similar clinical outcomes—so, you pay your money and take your choice. Full Text | PDF
Lung cancer: Defining standard of care for performance status 2—don't rush Cesare Gridelli Published online: 23 July 2013 p490 | doi:10.1038/nrclinonc.2013.134 The standard treatment for patients with advanced-stage non-small-cell lung cancer with a performance status of 2 is unclear because of the heterogeneity of this population. Although a recent trial suggests that carboplatin plus pemetrexed improves survival as compared to single-agent pemetrexed, we should be cautious when defining new standards of treatment on the basis of single small trials. Full Text | PDF
Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer? Robert C. Doebele Published online: 23 July 2013 p492 | doi:10.1038/nrclinonc.2013.135 Rearrangements of the ALK gene have been associated with sensitivity to crizotinib and other kinase inhibitors with activity against ALK. The phase III PROFILE 1007 randomized study of crizotinib versus chemotherapy has demonstrated that crizotinib is superior to standard second-line chemotherapy in ALK-positive non-small-cell lung cancer. Full Text | PDF
REVIEWS		Top
Luminal breast cancer: from biology to treatment Michail Ignatiadis & Christos Sotiriou Published online: 23 July 2013 p494 | doi:10.1038/nrclinonc.2013.124 Luminal breast cancer is the most-frequently occurring subtype of breast cancer, but it is a highly heterogeneous disease. Data are emerging to assist in the stratification of patients to the optimal treatment and to address therapy resistance. This Review outlines the biology of this disease, and discusses the treatment options and ongoing studies for women with oestrogen receptor-positive breast cancer. Abstract | Full Text | PDF
Image-guided cancer surgery using near-infrared fluorescence Alexander L. Vahrmeijer, Merlijn Hutteman, Joost R. van der Vorst, Cornelis J. H. van de Velde & John V. Frangioni Published online: 23 July 2013 p507 | doi:10.1038/nrclinonc.2013.123 Optical imaging that exploits invisible near-infrared (NIR) fluorescent light (700–900 nm) has the potential to improve cancer surgery outcomes, minimize anaesthesia time and lower health-care costs via its improved contrast and depth of tissue penetration relative to visible light. This Review introduces the concept of NIR fluorescence imaging and examines imaging system and contrast agent optimization. Abstract | Full Text | PDF
Clinical management of obese patients with cancer Wenjing Tao & Jesper Lagergren Published online: 16 July 2013 p519 | doi:10.1038/nrclinonc.2013.120 Evidence links obesity to increased cancer incidence, and possibly also to poorer cancer survival. Obese patients face a range of specific challenges related to the diagnosis and treatment of cancer. This Review summarizes the available literature addressing the clinical management of obese patients with cancer and discusses opportunities to improve the cancer care of these patients. Abstract | Full Text | PDF
Small bowel adenocarcinomas—existing evidence and evolving paradigms Kanwal Raghav & Michael J. Overman Published online: 30 July 2013 p534 | doi:10.1038/nrclinonc.2013.132 Small bowel adenocarcinomas are rare, histologically diverse tumours and their incidence worldwide is increasing. Despite this, research efforts have received comparatively little attention compared with other cancers with a similar incidence. The authors present an evidence-based approach to present-day management of small bowel adenocarcinoma, describe contemporary challenges and uncover evolving paradigms in the management of these rare neoplasias. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Earlier diagnosis of breast cancer: focusing on symptomatic women Georgios Lyratzopoulos & Gary Abel Published online: 23 July 2013 p544 | doi:10.1038/nrclinonc.2012.126-c1 Full Text | PDF
REPLIES		Top
Earlier diagnosis of breast cancer outside of a screening programme Chris I. Flowers Published online: 23 July 2013 p544 | doi:10.1038/nrclinonc.2012.126-c2 Full Text | PDF
Mammography screening and women with symptomatic breast cancer Philippe Autier Published online: 23 July 2013 p544 | doi:10.1038/nrclinonc.2012.126-c3 Full Text | PDF
Advertisement
UCSD Clinical and Translational Research Institute and Nature Medicine present: Bench to Bedside 2013: Cancer Therapeutics November 4-6, 2013 Estancia La Jolla Hotel La Jolla, CA, USA  Click here for more information or to register for this conference today!
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.